Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key MetricsFindings Highlight ...

According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response ...

Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...

LLC ("Zina") to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease. Under the terms of the agreement, Zina will provide comprehensive services related to ...

Based on the encouraging Phase 1 results, Ethris filed a Clinical Trial Application (CTA) for a Phase 2a rhinovirus challenge study in asthma patients, planned to begin in Q2 2025. This upcoming ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

Australian antiviral drug development company Island Pharmaceuticals has completed subject dosing for the phase 2b ...